AsiaMedic Limited FY2025 Financial Analysis: Strong Growth in Core Healthcare Operations
AsiaMedic Limited, a leading healthcare provider listed on SGX Catalist, has released its financial results for the year ended 31 December 2025. The report demonstrates robust operational progress, particularly in its core diagnostic imaging business, following recent capacity expansion and strategic portfolio optimisation.
Key Financial Metrics
| Metric |
FY2025 |
FY2024 |
YoY Change (%) |
| Total Revenue (S\$’000) |
35,221 |
28,915 |
+22% |
| PATMI (S\$’000) |
2,024 |
1,010 |
+100% |
| EBITDA (S\$’000) |
5,610 |
3,504 |
+60% |
| Net Assets (S\$’000) |
18,100 |
Not disclosed |
N/A |
| Dividend |
Not disclosed |
Not disclosed |
N/A |
Operational Performance & Strategic Actions
- Core Imaging Business: Diagnostic imaging remained the primary revenue contributor, benefiting from higher patient volumes and increased referrals. The expansion at Royal Square Medical Centre Novena played a significant role in meeting rising demand.
- Health Screening & Primary Healthcare: These segments provided stable recurring revenue supported by corporate programmes and preventive healthcare demand.
- Portfolio Optimisation: The Group disposed of a 60% interest in its aesthetic business, sharpening focus on core healthcare operations. This resulted in a gain on disposal and improved operating performance.
- Operating Expenses: Increased in line with business expansion, mainly due to higher manpower, facility-related, and financing costs associated with new equipment and capacity.
Exceptional Earnings & Asset Sales
- Exceptional Gain: PATMI doubled to S\$2.0 million, supported by improved operating performance and a gain on disposal of subsidiary (from derecognition of net liabilities of the aesthetic business).
- Asset Sale: Strategic divestment of the majority interest in the aesthetic segment allows AsiaMedic to maintain an associate interest while focusing on core services.
Financial Position
- AsiaMedic maintained a stable financial position, with net assets increasing to S\$18.1 million and healthy cash resources to support ongoing operations and strategic initiatives.
Chairman’s Statement
“FY2025 reflects steady operational progress as the Group begins to realise the benefits of investments made in recent years. While expansion-related costs continue to impact margins, we are encouraged by improving utilisation levels and remain focused on strengthening operational discipline and delivering sustainable performance. Following a challenging first half of 2025, performance improved in the second half, supported by underlying organic growth and contributions from our new centre in Novena under the Group’s expansion strategy. With our expanded capacity now operational and utilisation improving, we believe the Group is better positioned to deliver more consistent earnings growth going forward.”
The tone is positive, highlighting improved utilisation, operational discipline, and a focus on sustainable performance.
Outlook for FY2026
- Operating Momentum: The Group expects to benefit from the full-year contribution of expanded diagnostic imaging capacity and continued efforts to improve utilisation and efficiency.
- Management Focus: Strengthening referral networks, enhancing cost discipline, and driving sustainable growth are key priorities.
- Risks: Ongoing macroeconomic and healthcare cost pressures remain, but improving utilisation is expected to support performance.
Conclusion & Investment Recommendations
AsiaMedic delivered strong financial performance in FY2025, evidenced by significant YoY growth in revenue, EBITDA, and PATMI. The business is transitioning from investment-led expansion to operational scaling, with new capacity now contributing meaningfully. Strategic divestment of non-core assets has sharpened the Group’s focus and improved profitability. The outlook is positive, with management targeting improved efficiency and consistent earnings growth, though macroeconomic and cost pressures remain.
Recommendation for Current Holders:
If you currently hold AsiaMedic stock, consider maintaining your position. The company’s improved core business performance, operational scaling, and positive outlook suggest further earnings growth potential, though continued monitoring of cost pressures is advised.
Recommendation for Prospective Investors:
If you do not currently hold AsiaMedic stock, consider initiating a position if you have a positive view on the healthcare sector and are comfortable with the risks of ongoing macroeconomic headwinds. The Group’s strong performance, clear strategic direction, and improved operational efficiency provide a compelling entry point.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Please consult your financial advisor before making any investment decisions.
View AsiaMedic Historical chart here
